Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32888
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlroughani, Raed-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorAl Khaboori, Jabber-
dc.contributor.authorAlsharoqi, Isa Ahmed-
dc.contributor.authorAhmed, Samar F.-
dc.contributor.authorHassan, Ali-
dc.contributor.authorInshasi, Jihad-
dc.contributor.authorKrieger, Derk W.-
dc.contributor.authorShakra, Mustafa-
dc.contributor.authorShatila, Ahmed Osman-
dc.contributor.authorSzolics, Miklos-
dc.contributor.authorKhallaf, Mohamed-
dc.contributor.authorEzzat, Aly-
dc.date.accessioned2020-12-11T12:24:57Z-
dc.date.available2020-12-11T12:24:57Z-
dc.date.issued2020-
dc.date.submitted2020-11-26T13:13:41Z-
dc.identifier.citationTherapeutic Advances in Neurological Disorders, 13 , p. 1-13-
dc.identifier.issn1756-2856-
dc.identifier.urihttp://hdl.handle.net/1942/32888-
dc.description.abstractOver the past decade, the development of high-efficacy disease-modifying therapies (DMTs) has been responsible for more effective management of relapsing-remitting multiple sclerosis (RRMS). However, the gaps in optimal care for this complex disease remain. Alemtuzumab (Lemtrada (R)) is a highly efficacious DMT that shows better patient outcomes and therapeutic benefits, but its use is under-recognized in the Gulf region. Experts in the care of multiple sclerosis shared their opinions based on study data and daily clinical experience in identifying the appropriate patient profile suitable for alemtuzumab's therapeutic benefits. Age, disease activity and severity, disability status, physician experience, and economic condition are some of the key indicators for alemtuzumab use.-
dc.description.sponsorshipThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The meeting of the expert group was organized and funded by Sanofi Genzyme. A medical writer (Haniya Dawn Panizales, Ogilvy Health and Wellness) provided medical writing assistance. All authors edited the manuscript for intellectual content and approved the final version. The final responsibility for the content lies with the authors.-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.rightsThe Author(s), 2020. Article reuse guidelines:sagepub.com/journalspermissions. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).-
dc.subject.otheralemtuzumab-
dc.subject.otherdisease modifying therapies-
dc.subject.otherGulf region-
dc.subject.othermultiple sclerosis-
dc.subject.otherpatient profiles-
dc.subject.otherrelapsing-remitting-
dc.titleThe use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective-
dc.typeJournal Contribution-
dc.identifier.epage13-
dc.identifier.spage1-
dc.identifier.volume13-
local.format.pages13-
local.bibliographicCitation.jcatA1-
dc.description.notesAlroughani, R (corresponding author), Al Amiri Hosp, Dept Med, Div Neurol, Kuwait, Kuwait.-
dc.description.notesalroughani@gmail.com-
dc.description.otherAlroughani, R (corresponding author), Al Amiri Hosp, Dept Med, Div Neurol, Kuwait, Kuwait. alroughani@gmail.com-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
dc.identifier.doi10.1177/1756286420954119-
dc.identifier.pmid32973927-
dc.identifier.isiWOS:000570713200001-
dc.contributor.orcidAlroughani, Raed/0000-0001-5436-5804-
dc.identifier.eissn1756-2864-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Alroughani, Raed] Al Amiri Hosp, Dept Med, Div Neurol, Kuwait, Kuwait.-
local.description.affiliation[Van Wijmeersch, Bart] Univ Hasselt, Hasselt, Belgium.-
local.description.affiliation[Van Wijmeersch, Bart] Rehabil & MS Ctr Pelt, Pelt, Belgium.-
local.description.affiliation[Al Khaboori, Jabber] Khoula Hosp, Muscat, Oman.-
local.description.affiliation[Alsharoqi, Isa Ahmed] Salmaniya Med Complex, Manama, Bahrain.-
local.description.affiliation[Ahmed, Samar F.] Ibn Sina Hosp, Kuwait, Kuwait.-
local.description.affiliation[Hassan, Ali; Szolics, Miklos] Tawam Hosp, Al Ain, Abu Dhabi, U Arab Emirates.-
local.description.affiliation[Inshasi, Jihad] Rashid Hosp, Dubai, U Arab Emirates.-
local.description.affiliation[Krieger, Derk W.] Mediclin Hosp, Dubai, U Arab Emirates.-
local.description.affiliation[Shakra, Mustafa] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.-
local.description.affiliation[Shatila, Ahmed Osman] Al Mafraq Hosp, Abu Dhabi, U Arab Emirates.-
local.description.affiliation[Khallaf, Mohamed; Ezzat, Aly] Sanofi Genzyme, Dubai, U Arab Emirates.-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorAlroughani, Raed-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorAl Khaboori, Jabber-
item.contributorAlsharoqi, Isa Ahmed-
item.contributorAhmed, Samar F.-
item.contributorHassan, Ali-
item.contributorInshasi, Jihad-
item.contributorKrieger, Derk W.-
item.contributorShakra, Mustafa-
item.contributorShatila, Ahmed Osman-
item.contributorSzolics, Miklos-
item.contributorKhallaf, Mohamed-
item.contributorEzzat, Aly-
item.fullcitationAlroughani, Raed; VAN WIJMEERSCH, Bart; Al Khaboori, Jabber; Alsharoqi, Isa Ahmed; Ahmed, Samar F.; Hassan, Ali; Inshasi, Jihad; Krieger, Derk W.; Shakra, Mustafa; Shatila, Ahmed Osman; Szolics, Miklos; Khallaf, Mohamed & Ezzat, Aly (2020) The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. In: Therapeutic Advances in Neurological Disorders, 13 , p. 1-13.-
item.accessRightsOpen Access-
item.validationecoom 2021-
crisitem.journal.issn1756-2856-
crisitem.journal.eissn1756-2864-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1756286420954119.pdfPublished version194.02 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.